Mesoblast Limited (NASDAQ:MESO) Short Interest Update

Mesoblast Limited (NASDAQ:MESO) was the target of a significant decline in short interest during the month of July. As of July 15th, there was short interest totalling 373,300 shares, a decline of 18.9% from the June 30th total of 460,500 shares. Based on an average daily trading volume, of 219,200 shares, the short-interest ratio is currently 1.7 days.

Mesoblast Stock Performance

Mesoblast stock traded down $0.32 during trading on Tuesday, reaching $6.47. The company had a trading volume of 225,495 shares, compared to its average volume of 1,086,107. Mesoblast has a 12-month low of $1.61 and a 12-month high of $8.66. The stock’s 50 day moving average price is $7.37 and its two-hundred day moving average price is $5.13. The firm has a market capitalization of $738.74 million, a price-to-earnings ratio of -5.78 and a beta of 3.48.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on MESO shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Mesoblast in a research report on Thursday, June 20th. Piper Sandler raised shares of Mesoblast from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $4.00 to $11.00 in a research report on Tuesday, July 23rd. Finally, StockNews.com lowered shares of Mesoblast from a “hold” rating to a “sell” rating in a research report on Wednesday, May 8th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Mesoblast presently has a consensus rating of “Hold” and an average target price of $16.00.

Institutional Investors Weigh In On Mesoblast

A number of institutional investors have recently bought and sold shares of MESO. GAMMA Investing LLC grew its stake in Mesoblast by 50.1% during the second quarter. GAMMA Investing LLC now owns 4,981 shares of the company’s stock worth $34,000 after buying an additional 1,663 shares during the period. Perkins Coie Trust Co purchased a new stake in Mesoblast during the second quarter worth approximately $68,000. Chapin Davis Inc. grew its stake in Mesoblast by 50.0% during the second quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock worth $102,000 after buying an additional 5,000 shares during the period. Finally, Chase Investment Counsel Corp purchased a new stake in Mesoblast during the first quarter worth approximately $298,000. 1.43% of the stock is currently owned by hedge funds and other institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.